Complex, 3D Screening for Cancer Immunotherapy
Screening for potential anti-cancer immunotherapies benefits from 3D platforms to detect complex, multi-cell and multi-step effects on the immune system.
Watch this webinar to learn:
- Differences between 2D and 3D drug screening models
- How 3D cultures can mimic cancer cell-immune cell interactions
- How to maximize reproducibility in a 3D drug screening assay
Lindsey Ott, Ph.D.
View this on-demand webinar to hear from 3D drug screening experts: Lisa Stehno-Bittel, Ph.D., President & Founder; and Lindsey Ott, Ph.D., Director of Product Innovation at Likarda LLC.
Screening for potential anti-cancer immunotherapies requires appropriately complex early screening tools to detect complex, multi-cell and multi-step effects on the immune system. 3D drug screening has the potential to meet these requirements; however, scaling 3D drug screening to a high-throughput, commercial level has been difficult. This talk will review the latest methods available for complex immunotherapy screening.
Who should watch:
- Assay development researchers
- Cancer immunotherapy researchers
- Cell biologists
About Our Speakers
Lisa Stehno-Bittel, Ph.D. co-founded Likarda in 2012. In 17 months, Likarda was revenue positive and was chosen as one of the top 50 Most Promising Start-Ups in the World. With over 25 years of experience studying cell biology and diabetes, she has over 65 publications and many awards. Lisa holds a part-time faculty position at the University of Kansas Medical Center, where she chaired a department prior to 2015. Lisa’s work in immunosuppression of autoimmune-induced type 1 diabetes was identified as a Key Scientific Discovery by Global Medical Discovery. Currently, Lisa and her team at Likarda are developing a cell-based solution for dogs with diabetes, removing the need for daily insulin injections.
Lindsey Ott, Ph.D. is the Director of Product Innovation at Likarda LLC. Her graduate research focused on biomaterials and tissue engineering, specifically developing biomaterial implants to treat tracheal stenosis in pediatric patients. Lindsey designed a synthetic nanofiber scaffold that could replace rib cartilage as an option to expand the trachea for infants and toddlers with a narrowed airway. In her role at Likarda, Lindsey expands Likarda’s patented 3D cell cluster technology into other preclinical drug discovery applications like oncology, immunotherapies, and ADME-Tox. She has published work in the fields of tracheal tissue engineering, biomaterial fabrication, adult mesenchymal stem cells for musculoskeletal tissue engineering, and preclinical drug discovery using 3D hepatic organoids.
Lisa Stehno-Bittel, Ph.D.